Aegis Capital Corp. acted as Sole Bookrunner on a $16.0 Million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW)

Rhea-AI Summary

Aegis Capital Corp. acted as Sole Bookrunner for a $16.0 million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW). The company is focused on respiratory treatments with its innovative Augmented Respiration Technology that stabilizes oxygen saturation levels, allowing patients to remain awake during treatment.

This technology aims to reduce reliance on mechanical ventilation, which is often invasive and risky.

Positive

• Successful IPO raising $16.0 million, potentially enhancing operational capabilities.
• Innovative Augmented Respiration Technology could disrupt respiratory treatment, attracting future investments.

Negative

• Possible dilution of shares due to the new offering.

NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $16.0 Million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)

About Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology, which immediately elevates and stabilizes patient oxygen saturation levels. The Company's ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky and costly mechanical ventilation systems that require medically induced coma.

About Aegis Capital Corporation

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

For more information about this offering or Investment Banking Services please email InvestmentBanking@aegiscap.com or call (212) 813-1010

www.aegiscapcorp.com

Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

SOURCE: Aegis Capital Corp.

View source version on accesswire.com:
https://www.accesswire.com/656130/Aegis-Capital-Corp-acted-as-Sole-Bookrunner-on-a-160-Million-Initial-Public-Offering-of-Common-Units-for-Inspira-Technologies-OXY-BHN-Ltd-NASDAQ-IINN-IINNW

FAQ

What is the purpose of the $16.0 million IPO by Inspira Technologies?

The funds from the IPO will enhance operational capabilities and further develop Inspira Technologies' respiratory treatment solutions.

How does Inspira Technologies' Augmented Respiration Technology work?

The technology stabilizes patient oxygen saturation levels, allowing for treatment without the need for invasive mechanical ventilation.

What is the potential impact of the IPO on Inspira Technologies' stock?

The IPO may lead to dilution of shares, impacting existing shareholders.

Who acted as the Sole Bookrunner for Inspira Technologies' IPO?

Aegis Capital Corp. served as the Sole Bookrunner for the IPO.